Open an account

Nymox Pharmaceutical

NYMXF · OTC

$0.06+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.06

About NYMXF

Nymox Pharmaceutical Corp. engages in the research and development of products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The firm also has a patent portfolio covering its marketed products, its investigational drugs, as well as other therapeutic and diagnostic indications. The company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Its products also include NicAlert and TobacAlert. NicAlert is a simple test to determine smoking status. The company is an easy-to-read test strip that can be used with either a saliva or a urine sample. TobacAlert is a home test that provides a quick, accurate, on-the-spot determination of a person’s level of exposure to tobacco products, including second-hand smoke.

Employees
3
Headquarters
Saint-Laurent, Quebec
Listed
Nov 26, 1997
Sector
Health Care
Industry
Biotechnology
Website
nymox.com

NYMXF key statistics

Market cap
6.30M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
13.20K
Volume
14.00K
Open price
$0.04
High today
$0.06
Low today
$0.04
52 Week high
$0.1999
52 Week low
$0.0002

Nymox Pharmaceutical (NYMXF) at a glance

As of Oct 23, 2026, Nymox Pharmaceutical (NYMXF) shares are priced at $0.06, giving the company a market cap of 6.30M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.04 and $0.06. The current price is 50.0% above the day's low and 0.0% below its high.

Volume so far is 14.00K shares, in line with the average of 13.20K shares a day.

Over the past year Nymox Pharmaceutical has ranged from $0.0002 to $0.1999, and now sits 30% of the way up that range.

Nymox Pharmaceutical met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY23 it reported -$0.01 per share against an estimate of $0.00.

NYMXF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 30.9% on average.

  1. Q2 FY12: reported -$0.05 per share against an estimate of -$0.0607
  2. Q3 FY12: reported -$0.04 per share against an estimate of -$0.0607
  3. Q4 FY12: reported -$0.08 per share against an estimate of -$0.0767
  4. Q1 FY13: reported -$0.03 per share against an estimate of -$0.046
  5. Q3 FY13: reported -$0.03 per share against an estimate of -$0.0531
  6. Q4 FY13: reported -$0.04 per share against an estimate of -$0.0531
  7. Q2 FY23: reported -$0.01 per share against an estimate of $0.00
  8. Q3 FY23: reported -$0.01 per share against an estimate of $0.00

NYMXF news

  • Press releaseACCESS Newswire

    Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean

Similar companies

Companies in the same industry as Nymox Pharmaceutical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.